Trial
NCT02848001
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Celgene
Collaborators
—
Condition
Leukemia, Myeloid, Acute
Intervention
CC-90009
Why stopped
Trial terminated because of lack of efficacy in the short term acute phase.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-12